Electromed, Inc. (NYSE Amex: ELMD) today announced financial results for the three-month period ended September 30, 2011. Net Revenues for the three months ended September 30, 2011 were approximately $5,379,000, a 29.1% increase compared to Net Revenues of approximately $4,165,000 for the same period last year. The Company also announced Net Income of approximately $246,000, or $0.03 per basic and diluted share, for the three months ended September 30, 2011, compared to Net Income of approximately $112,000, or $0.02 per basic and diluted share, for the same period last year. Net Revenues increased in correlation with the expansion of the sales force. Net Income results were attributable to higher Net Revenues, offset by increased expenses related to increases in sales force. Research investments, additions to senior management, and additional facilities have all added to expenses in the first quarter.

Robert Hansen, Chairman and CEO, commented on the Company, saying, “In very uncertain times, Electromed, Inc. continues to execute successfully on its business plans. The Company is committed to building a platform in sales, product innovation, and patient services sufficient to assure its expanding position in airway clearance therapy.”

Gross Profit increased to approximately $4,058,000, or 75.4% of Net Revenues, for the three months ended September 30, 2011, compared to $2,934,000, or 70.4% for the same period in Fiscal 2011. The increase in Gross Profit dollars resulted primarily from the increase in Sales volume. The change in Gross Profit percentage for the three-month period ended September 30, 2011, was primarily the result of higher reimbursement from the mix of referrals and approvals compared to the three-month period ended September 30, 2010. Factors such as diagnoses that are not assured of reimbursement, along with insurance programs which present lower allowable reimbursement amounts (for example, state Medicaid programs) affect average reimbursement received on a short-term basis and tend to cause margins to fluctuate on a quarterly basis.

Operating Expenses, which consist of Selling, General, and Administrative Expenses and Research and Development expenses, were approximately $3,605,000 for the three months ended September 30, 2011, an increase of approximately 34.2% over total Operating Expenses for the same period last year. These planned increases resulted from higher payroll and marketing expenses related to increasing the size of the sales team, increases in reimbursement, administration, patient services staff, and patient training costs related to the higher Sales volume, increased expenses relating to being a new public Company, and increased Research and Development expenses.

Total cash was approximately $2,946,000 as of September 30, 2011. For the three months ended September 30, 2011, cash used in financing activities was approximately $86,000, consisting of primarily $110,000 on payments of Long-term Debt and capital lease obligations offset by proceeds from a warrant exercise and subscription notes receivable of approximately $24,000. An aggregate of $237,000 was used for investing activities during the three months ended September 30, 2011, including $22,000 in payments for patent-related costs and $215,000 in expenditures for property and equipment. The Company used approximately $823,000 in operating activities composed primarily of an increase in the Company’s receivable position, which increased approximately $807,000, or 8.4% to approximately $10,400,000 during the three months ended September 30, 2011.

About Electromed, Inc.Electromed, Inc., founded in 1992 and headquartered in New Prague, Minnesota, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest ® Airway Clearance System and related products, to patients with compromised pulmonary function. Further information about the Company can be found at www.electromed.com.

Cautionary Statements Certain statements found in this release may constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect the speaker’s current views with respect to future events and financial performance and include any statement that does not directly relate to a current or historical fact. Forward-looking statements can generally be identified by the words “believe,” “expect,” “anticipate” or “intend” or similar words. Forward-looking statements made in this release include the Company’s plans and expectations regarding sales growth and product innovation. Forward-looking statements cannot be guaranteed and actual results may vary materially due to the uncertainties and risks, known and unknown, associated with such statements. Examples of risks and uncertainties for Electromed include, but are not limited to, the impact of emerging and existing competitors, the effectiveness of our sales and marketing initiatives, changes to reimbursement programs, as well as other factors described from time to time in our reports to the Securities and Exchange Commission (including our Annual Report on Form 10-K). Investors should not consider any list of such factors to be an exhaustive statement of all of the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this release.
 
Electromed, Inc. and Subsidiary
Condensed Consolidated Balance Sheets
    September 30     June 30
2011 2011
Assets (Unaudited)
Current Assets
Cash and cash equivalents $ 2,946,173 $ 4,091,739
Accounts receivable (net of allowances for doubtful accounts of $45,000) 10,400,466 9,593,105
Inventories 2,163,802 1,855,957
Prepaid expenses and other current assets 419,203 371,257
Deferred income taxes   722,000     722,000  

Total current assets
16,651,644 16,634,058
Property and equipment, net 3,070,662 2,807,082
Finite-life intangible assets, net assets, net 1,227,572 1,235,828

Other assets
  217,907     191,964  
Total assets $ 21,167,785   $ 20,868,932  
 
Liabilities and Shareholders’ Equity
Current Liabilities
Revolving line of credit $ 1,768,128 $ 1,768,128
Current maturities of long-term debt 403,745 438,267
Accounts payable 758,986 733,621
Accrued compensation 906,425 868,229
Warranty reserve 475,019 444,096

Other accrued liabilities
  174,613     161,166  
Total current liabilities 4,486,916 4,413,507
Long-term debt, less current maturities 1,506,654 1,582,102
 
Deferred income taxes   167,000     167,000  
Total liabilities   6,160,570     6,162,609  
 
Commitments and Contingencies (Note 8)
 
Shareholders’ Equity

Common stock, $0.01 par value; authorized: 13,000,000; shares; issued and outstanding: 8,101,085 and 8,100,485 shares respectively
81,011 81,005
Additional paid-in capital 12,827,215 12,794,368
Retained earnings 2,098,989 1,853,450
 
Common stock subscriptions receivable for 15,000 shares outstanding as of June 30, 2011   -     (22,500 )
Total shareholders’ equity   15,007,215     14,706,323  
Total liabilities and shareholders’ equity $ 21,167,785   $ 20,868,932  
 
 
Electromed, Inc. and Subsidiary
Condensed Consolidated Statements of Income
(Unaudited)     For the Three Months Ended
September 30,
2011     2010
 
Net revenues $ 5,378,918 $ 4,165,429
Cost of revenues   1,321,318     1,231,690  
Gross profit   4,057,600     2,933,739  
 
Operating expenses
Selling, general and administrative 3,397,553 2,487,595
Research and development   207,585     198,386  
Total operating expenses   3,605,138     2,685,981  
Operating income 452,462 247,758
Interest expense, net of interest income of $2,027 and $1,971 respectively   43,923     59,688  
Net income before income taxes 408,539 188,070
 
Income tax expense   (163,000 )   (76,000 )
Net income $ 245,539   $ 112,070  
 
Earnings per share attributable to Electromed, Inc. common shareholders:
Basic $ 0.03   $ 0.02  
Diluted $ 0.03   $ 0.02  
 
Weighted-average Electromed, Inc. common shares outstanding:
Basic   8,100,915     6,986,798  
Diluted   8,119,190     7,002,904  
 
 
Electromed, Inc. and Subsidiary
Condensed Consolidated Statements of Cash Flows
(Unaudited)     For the Three Months Ended
September 30,
2011     2010
Cash Flows From Operating Activities
Net income $ 245,539 $ 112,070
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation 90,552 78,684
Amortization of finite-life intangible assets 30,006 25,721
Amortization of debt issuance costs 3,297 13,408
Share-based compensation expense 31,053 42,900
Loss on disposal of property and equipment 9,864 2,385
Changes in operating assets and liabilities:
Accounts receivable (807,361 ) (470,716 )
Inventories (307,845 ) 35,730
Prepaid expenses and other assets (77,186 ) (96,234 )
Accounts payable and accrued liabilities   (40,754 )   194,943  
Net cash used in operating activities   (822,835 )   (61,109 )
 
Cash Flows From Investing Activities
Expenditures for property and equipment (215,311 ) (97,544 )
Expenditures for finite-life intangible assets   (21,750 )   (196,332 )
Net cash used in investing activities   (237,061 )   (293,876 )
 
Cash Flows From Financing Activities
Net borrowings on revolving line of credit - (500,000 )
Principal payments on long-term debt including capital lease obligations (109,970 ) (105,428 )
Payments of deferred financing fees - (4,659 )
Proceeds from warrant exercises 1,800 -
Proceeds from sales of 1.9 million shares of common stock, net of offering costs of $1,229,882 - 6,370,118
Proceeds from subscription notes receivable   22,500     -  
Net cash provided by (used in) financing activities   (85,670)     5,760,031  
Net increase (decrease) in cash and cash equivalents (1,145,566) 5,405,046
Cash and cash equivalents
Beginning of period   4,091,739     610,727  
End of period $ 2,946,173   $ 6,015,773  
 

Copyright Business Wire 2010

If you liked this article you might like

Analysts' Actions -- HD Supply, JD.com, Sarepta, Wells Fargo and More

Analysts' Actions -- HD Supply, JD.com, Sarepta, Wells Fargo and More

7 Stocks Under $10 to Trade for Big Profits

7 Stocks Under $10 to Trade for Big Profits

Electromed (ELMD) Strong On High Relative Volume Today

Electromed (ELMD) Strong On High Relative Volume Today

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

3 Stocks Pushing The Health Services Industry Lower

3 Stocks Pushing The Health Services Industry Lower